Vaxart garners $20M VC round for vaccine pills

San Francisco-based Vaxart has raised $20 million to back its work developing easy-to-take vaccine pills. The 9-year-old biotech revealed the raise in a Form D filed with the SEC. Just a few weeks ago Vaxart reported positive data from a Phase I study of its H1N1 flu vaccine in tablet form. A $12.5 million Series B financing led by Care Capital was closed back in 2010. Form D

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.